Literature DB >> 9567205

Surgery of the rheumatoid foot and ankle.

B C Toolan1, S T Hansen.   

Abstract

Numerous reconstructive procedures have been used to address the manifestations of rheumatoid arthritis in the foot and ankle. Clinical studies have documented that these procedures relieve pain, however they often sacrifice motion essential to the normal function of the foot. In the forefoot, metatarsophalangeal joint resection arthroplasty shortens the lever arm of the foot, defunctions the toes, and disables the plantar plate and fat pad. Arthrodesis of the ankle and hindfoot alters gait and the effective transmission of weight-bearing stresses through the foot and ankle. These ablative procedures may provoke the deterioration of adjacent joints and may cripple the long-term function of the lower extremity. The introduction of reconstructive procedures designed to preserve motion in joints essential to function and the recognition and treatment of muscle imbalances associated with bone and joint deformities are recent advances in the surgical management of the rheumatoid foot and ankle.

Entities:  

Mesh:

Year:  1998        PMID: 9567205     DOI: 10.1097/00002281-199803000-00005

Source DB:  PubMed          Journal:  Curr Opin Rheumatol        ISSN: 1040-8711            Impact factor:   5.006


  3 in total

1.  [Talonavicular arthrodesis for the rheumatoid foot].

Authors:  H-D Carl; D Pfander; G Weseloh; B Swoboda
Journal:  Z Rheumatol       Date:  2006-11       Impact factor: 1.372

2.  High-grade MRI bone oedema is common within the surgical field in rheumatoid arthritis patients undergoing joint replacement and is associated with osteitis in subchondral bone.

Authors:  F M McQueen; A Gao; M Ostergaard; A King; G Shalley; E Robinson; A Doyle; B Clark; N Dalbeth
Journal:  Ann Rheum Dis       Date:  2007-05-09       Impact factor: 19.103

3.  [Long-term results of synovectomy in the rheumatoid ankle joint].

Authors:  S Anders; J Schaumburger; S Kerl; S Schill; J Grifka
Journal:  Z Rheumatol       Date:  2007-11       Impact factor: 1.372

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.